



# PROVIDER LED ENTITY

## Coronary Artery Disease AUC:

### 2023 Update

09/12/2023

### **Appropriateness of advanced imaging procedures\* in patients with coronary artery disease (suspected or diagnosed):**

\*including CT coronary artery calcium (CAC), coronary CT angiography (CCTA), stress cardiac MRI (CMR), and stress radionuclide myocardial perfusion imaging (PET or SPECT) – stress echocardiography, exercise ECG, and invasive coronary angiography also included

**Abbreviation list:**

ACC	American College of Cardiology
ACCF	American College of Cardiology Foundation
ACR	American College of Radiology
AHA	American Heart Association
AUC	Appropriate Use Criteria
CABG	Coronary artery bypass grafting
CAC	Coronary artery calcium
CAD	Coronary artery disease
CCTA	Coronary CT angiography
CHD	Coronary heart disease
CI	Confidence interval
CMR	Cardiac MRI
CT	Computed tomography
CVD	Cardiovascular disease
EACI	European Association of Cardiovascular Imaging
ECG	Electrocardiography
ESC	European Society of Cardiology

FFR	Fractional flow reserve
FT	Functional testing
ICA	Invasive coronary angiogram
IHD	Ischemic heart disease
MPI	Myocardial perfusion imaging
MRI	Magnetic resonance imaging
NICE	National Institute for Health and Care Excellence
NPV	Negative predictive value
PCI	Percutaneous coronary intervention
PET	Positron emission tomography
PLE	Provider Led Entity
PPV	Positive predictive value
PTP	Pre-test probability
PVC	Premature ventricular contraction
RNI	Radionuclide imaging
SNMMI	Society of Nuclear Medicine and Molecular Imaging
SPECT	Single-photon emission computed tomography

# Appropriate Use Criteria: How to Use this Document

*The CDI Quality Institute follows the recommendation framework defined by the Appraisal of Guidelines for Research & Evaluation (AGREE II), AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) and a modified version of the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) to evaluate the strength of recommendations concerning advanced imaging. Considerations used to determine a recommendation are listed below.*

**Primary recommendation (green):** A strong recommendation for initial imaging for this presentation; there is confidence that the desirable effects of imaging outweigh its undesirable effects.

**Alternative recommendation (yellow):** A conditional recommendation for imaging; the desirable effects of imaging likely outweigh its undesirable effects, although some uncertainty may exist. The individual patient's circumstances, preferences, and values should be considered on a case-by-case basis. This may include: contraindication to the primary recommendation, specific clinical circumstances that require use of the alternative recommendation, or the primary recommendation has results that are inconclusive or incongruent with the patient's clinical diagnosis.

**Recommendation against imaging (red):** The undesirable effects of imaging outweigh any desirable effects. Additionally, the recommendation may be impractical or not feasible in the targeted population and/or practice setting(s).

## **Coronary Artery Disease AUC Summary:**

In **asymptomatic** patients with suspected coronary artery disease (CAD), an initial assessment of global risk is recommended. If a risk-based treatment decision is uncertain, CT coronary artery calcium (CAC) may be used to further define the patient's risk level. CAC is a sensitive technique to detect and quantify the coronary calcium load, a marker of atherosclerosis. Imaging with stress modalities or coronary CT angiography (CCTA) can also be useful for select patients based on the clinical likelihood of CAD and other specific risk factors.

When **symptoms** are present and coronary artery disease is a consideration, assessment of a patient's pretest probability (PTP) of CAD is indicated using a validated risk assessment tool. Information concerning risk factors, resting ECG findings, and/or coronary calcification scores can improve risk assessment. Diagnostic testing in those with a PTP < 5% should only be performed for compelling reasons. When the PTP is 5-15%, factors such as patient preference, resource availability, and clinical judgment are important considerations for testing. Anatomic (e.g., CCTA) or functional/stress imaging is generally appropriate whenever the patient has a high risk of CAD (> 15%) or if specific conditions are present (e.g., confirmed heart failure, ventricular tachycardia, frequent PVCs). CCTA has a high negative predictive value and excellent diagnostic accuracy. It is preferred in patients with a low-to-intermediate range of CAD probability, no previous diagnosis of CAD, and when good image quality is likely. However, recommendations generally require 64-slice CT as a minimum threshold for use, which may limit accessibility. Functional imaging can demonstrate myocardial perfusion or contraction abnormalities. It typically has better rule-in power and may be preferred for those at the higher end of the range of clinical likelihood. The choice of anatomic vs. functional testing and the choice of a specific modality may ultimately depend on local expertise and experience, patient preferences and characteristics, and any contraindications to imaging (e.g., inability to exercise, bronchospastic disease, claustrophobia, allergies to contrast, presence of metal implants).

**Follow-up or sequential testing** can be useful for asymptomatic patients with an intermediate-to-high global CAD risk and when previous testing was performed > 2 years prior. It is also generally appropriate

when a previous test was equivocal or abnormal, and/or if the patient is symptomatic. In patients with a history of **revascularization**, additional testing can be used if there are new symptoms or if it has been determined that prior revascularization was incomplete. In select cases, further testing following left main coronary stenting, at > 5-year intervals after coronary artery bypass graft (CABG) surgery, or at > 2-year intervals after percutaneous coronary intervention (PCI) may be appropriate.

### **Definitions & assumptions:**

- **CT coronary artery calcium (CAC):** Cardiac CT for quantitative evaluation of coronary artery calcification using either electron beam CT or multi-detector CT.
- **Functional imaging:** Functional tests for CAD detect myocardial ischemia through ECG changes, wall motion abnormalities (stress CMR or stress echocardiography), or perfusion changes (SPECT, PET, myocardial contrast echocardiography, or contrast CMR) (Knuuti et al [ESC] 2020). The mode of stress testing is preferred to be exercise for those able to do so (Gulati et al [AHA et al] 2021). For those unable to exercise or with ECG abnormalities that prevent interpretation of the ST-segment changes during stress, it is assumed that pharmacological stress is performed (Verberne et al 2015; Henzlova et al 2016). For CMR, it is assumed that vasodilator stress perfusion is used (Wolk et al [ACCF et al] 2014).
  - **PET imaging:** Commonly used radiopharmaceuticals for PET imaging include ammonia (<sup>13</sup>NH<sub>3</sub>), rubidium chloride (<sup>82</sup>RbCl) and 2-(<sup>18</sup>F) FLURO-2DEOXY-D-GLUCOSE (FDG).
  - **SPECT imaging:** Commonly used radiopharmaceuticals for SPECT imaging include Thallium-201 Chloride, Technetium-99m Sestamibi, and Technetium-99m Tetrofosmin.
- **Anatomical imaging:** Non-invasive anatomic testing for CAD directly visualizes the coronary artery lumen and wall using multidetector CT (usually 64-slice or higher) and intravenous contrast agent. It provides high accuracy for the detection of obstructive coronary stenosis similar to that of catheterization, as well as plaque analysis and morphological information (Knuuti et al [ESC] 2020). Intermediate levels of stenosis (50-80%) may not be functionally significant, however, and functional testing is typically recommended for further evaluation in these patients.
  - **CT derived fractional flow reserve (FFR-CT):** While not a stand-alone service, the ability to measure FFR by CT has the potential to expand the clinical application of CCTA in clinically stable symptomatic CAD patients where available (e.g., Norgaard et al 2014; Driessen et al 2019). It should not be used in those with contraindications to CCTA, including extensive coronary calcification and/or arrhythmias, or in post-CABG patients (*CMS Local Coverage Determination* 2021) Thus, recommendations throughout this document for CCTA should assume “with or without fractional flow reserve assessed by CT (FFR-CT)”.
  - While beyond the scope of this document, the Coronary Artery Disease Reporting and Data System (*CAD-RADS*) was created to standardize reporting systems for patients undergoing CCTA and to guide possible next steps in patient management (Cury et al 2022).

---

## PICO 1: Initial evaluation for coronary artery disease in asymptomatic patient without known coronary artery disease

### Low global CAD risk\*:

- **Yellow** – CT coronary artery calcium
- **Red** – Stress ECG
- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress echocardiography
- **Red** – Stress cardiac MRI
- **Red** – Coronary CT angiography
- **Red** – Invasive coronary angiography

### Intermediate global CAD risk:

- **Green** – CT coronary artery calcium
- **Yellow** – Stress ECG
- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress echocardiography
- **Red** – Stress cardiac MRI
- **Red** – Coronary CT angiography
- **Red** – Invasive coronary angiography

### High global CAD risk\*\*:

- **Green** – Stress ECG
- **Yellow** – Coronary CT angiography
- **Yellow** – Stress echocardiography
- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress cardiac MRI
- **Yellow** – CT coronary artery calcium\*\*\*
- **Red** – Invasive coronary angiography

\*Asymptomatic patients considered to be at low risk of CAD do not typically require advanced imaging (Ghoshhajra et al [ACR] 2021; Greenland et al [ACCF/AHA] 2010: class III recommendation (no benefit), level B evidence; Greenland et al [ACCF/AHA] 2007).

\*\*In addition to those categorized as “high risk” on a global risk score, also includes patients with previous CAC score  $\geq 400$ , diabetes, family history of premature CVD or hyperlipidemia, chronic kidney disease, and/or known atherosclerotic vascular disease (Greenland et al [ACCF/AHA] 2007; Knuuti et al [ESC] 2020; Schindler et al [SNMMI et al] 2020).

\*\*\*If CAC score has not been previously assessed and the patient is not already a candidate for intensive risk reducing therapy.

Level of Evidence: CT coronary artery calcium: moderate; stress radionuclide myocardial perfusion imaging: moderate; stress cardiac MRI: low; coronary CT angiography: low; stress echocardiography: moderate

Notes concerning applicability and/or patient preferences: It is recommended to take account for locally available technology and expertise, the person and their preferences, and any contraindications (e.g., disabilities, frailty, limited ability to exercise, claustrophobia, metal implants, allergy to contrast) when deciding on the imaging method (*NICE* 2016). If more than one modality falls into the same appropriate use category, it is assumed that physician judgment and available local expertise are used to determine the correct test for an individual patient (Winchester et al [ACC et al] 2023). The patient should be engaged in a process of shared decision-making before determining the final choice of the cardiac test modality (Gulati et al [AHA et al] 2021).

When considering testing that includes an exercise component, it should be assumed that the patient has no limitations that would preclude exercising to a symptomatic endpoint, achieving at least 80% of their age- and sex-predicted workload or  $\geq 85\%$  of their age-predicted maximal heart rate (Winchester et al [ACC et al] 2023). Similarly, it should be assumed that the ECG is interpretable. Baseline abnormalities that prevent interpretation of the ST-segment changes during stress includes those ECGs with resting abnormalities, such as ST-segment depression ( $\geq 0.10$  mV), left bundle branch block (LBBB), Wolff-Parkinson-White syndrome, digoxin use, or a ventricular paced rhythm that would make the exercise ECG difficult to interpret (Knuuti et al [ESC] 2020; PLE expert panel consensus opinion).

In the recommendations, 64-slice CT is generally required as a minimum threshold for coronary CT angiography, which may limit accessibility.

Guideline and PLE expert panel consensus opinion summary:

The identification of those patients who may benefit from early intervention prior to development of symptoms has been shown to reduce mortality and morbidity (Ghoshhajra et al [ACR] 2021). In an effort to lower the high burden of coronary deaths in asymptomatic adults, numerous measurements of risk factors and risk markers, as well as stress tests, are often performed as screening investigations, particularly in those patients with high risk (Knuuti et al [ESC] 2020).

**Global risk assessment**

Assessment of risk is recommended in every patient being evaluated for suspected CAD (Greenland et al [ACCF/AHA] 2010; Knuuti et al [ESC] 2020). Risk assessment in asymptomatic individuals stratifies patients based on a 10-year risk of cardiovascular mortality (*USPSTF* 2018a; *USPSTF* 2018b). Several traditional risk factors are associated with higher risk for CVD events: older age, male sex, high blood pressure, current smoking, abnormal cholesterol levels, diabetes, obesity, and physical inactivity (*USPSTF* 2018a). Global risk scores (*Framingham Risk Score*, *Reynolds Risk Score*, *Systematic Coronary Risk Evaluation [SCORE]*, *ASCVD risk calculator*, etc.) have used these risk factors to categorize patients in broad terms as “low risk”, “intermediate risk”, and “high risk” (Greenland et al [ACCF/AHA] 2010; *USPSTF* 2018a). In general, there is agreement that persons with a 10-year CVD event risk  $> 20\%$  are high risk (Greenland et al [ACCF/AHA] 2010; Winchester et al [ACC et al] 2023; *USPSTF* 2018a; Grundy et al [AHA et al] 2019). The threshold for dividing low- from intermediate-risk is not uniform, however, with scores proposing cutoff values anywhere from  $< 5\%$  to  $< 10\%$  risk over 10 years (Greenland et al [ACCF/AHA] 2010; Winchester et al [ACC et al] 2023; *USPSTF* 2018a; Grundy et al [AHA et al] 2019; Ghoshhajra et al [ACR] 2021). In general, these risk factors are strong markers for disease at a population level but rather poor risk discriminators for CAD on an individual level (Greenland et al [ACCF/AHA] 2010; Ghoshhajra et al [ACR] 2021).

Clinical judgment can be used to modify assessments of global risk for cardiovascular disease. Diabetes, chronic kidney disease and known atherosclerotic vascular disease (e.g., peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease, stroke, or TIA) may indicate a high risk for CAD and preclude further evaluation of risk (Greenland et al [ACCF/AHA] 2007; Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020). A family history of premature CAD (< 55 years of age in men or < 65 years of age in women) is also of significant consideration in the assessment of risk (Winchester et al [ACC et al] 2023; Greenland et al [ACCF/AHA] 2010), and these subjects should be screened for familial hypercholesterolemia (Knuuti et al [ESC] 2020: class I, level B evidence). Patients with chronic inflammatory diseases (e.g., psoriasis, RA, lupus, or HIV/AIDS) and those undergoing treatment for cancer (with radiation to the chest or vasotoxic chemotherapeutic agents) may also need additional evaluation and counseling (Knuuti et al [ESC] 2020).

If, after quantitative risk assessment, a risk-based treatment decision is uncertain, a resting ECG or echocardiogram may be appropriate (Greenland et al [ACCF/AHA] 2010: level B/C evidence; Knuuti et al [ESC] 2020). Assessment of CT CAC score, along with high-sensitivity C-reactive protein (hs-CRP), carotid artery ultrasound, and/or ankle-brachial index (ABI), may also be considered in select patients to further inform treatment decision making (Goff et al [ACC/AHA] 2014: class IIb recommendation, level B evidence; Greenland et al [ACCF/AHA] 2010: class IIa, level B evidence; Knuuti et al [ESC] 2020: class IIb, level B evidence; Grundy et al [AHA et al] 2019). The *US Preventive Services Task Force* notes, however, that the current evidence is insufficient to assess the balance of benefits and harms of routinely adding these nontraditional risk factors to cardiovascular disease risk assessment (USPSTF 2018a).

### **Stress ECG**

In those who can exercise, an exercise ECG may be appropriate for cardiovascular risk assessment in asymptomatic subjects with intermediate or high global risk (Greenland et al [ACCF et al] 2010: class IIb, level B evidence; Winchester et al [ACC et al] 2023). An exercise ECG is rarely appropriate for asymptomatic patients at low risk, and of no diagnostic value in patients with ECG abnormalities that prevent interpretation of the ST-segment changes during stress (including LBBB, paced rhythm, Wolff-Parkinson-White syndrome,  $\geq 0.1$  mV ST-segment depression on resting ECG, or those treated with digitalis) (Knuuti et al [ESC] 2020; Winchester et al [ACC et al] 2023; USPSTF 2018b: grade D recommendation; PLE expert panel consensus opinion).

### **CT coronary artery calcium (CAC)**

Studies have shown that CT CAC score can predict future mortality and major cardiac events, and aids in improving risk-stratification beyond conventional risk factor-based scores alone (Ghoshhajra et al [ACR] 2021). Measurement of coronary artery calcium with noncontrast CT is primarily helpful for use in asymptomatic patients with intermediate global risk (Winchester et al [ACC et al] 2023; Ghoshhajra et al [ACR] 2021; Greenland et al [ACCF/AHA] 2007; Greenland et al [ACCF/AHA] 2010: class IIa recommendation, level B evidence; PLE expert panel consensus opinion). The presence of an elevated CAC score ( $\geq 400$ ) increases the likelihood of obstructive CAD and risk of events, especially in patients with multiple coronary risk factors (Schindler et al [SNMMI et al] 2020). CAC measurement is not always advised in asymptomatic patients with high CHD risk, as they may already be candidates for intensive risk reducing therapies (Greenland et al [ACCF et al] 2007). CT CAC measurement is not indicated in patients considered to be at low risk for CHD (Ghoshhajra et al [ACR] 2021; Greenland et al [ACCF/AHA] 2010: class III recommendation (no benefit), level B evidence; Greenland et al [ACCF/AHA] 2007). In addition, CT scanning should generally not be done in men < 40 and women < 50 due to the very low prevalence of detectable calcium in these age groups (Greenland et al [ACCF/AHA] 2010).

### **Stress radionuclide myocardial perfusion imaging (PET or SPECT)**

In asymptomatic patients with a low or intermediate pretest global CAD risk, the use of stress perfusion imaging is rarely appropriate (Knuuti et al [ESC] 2020: class III, level C recommendation; Schindler et al [SNMMI et al] 2020: score 1, score 2; Greenland et al [ACCF/AHA] 2010: level C evidence; Winchester et al [ACC et al] 2023; Ghoshhajra et al [ACR] 2021). In asymptomatic patients with a higher pretest global CAD risk, available data suggest a possible role for stress perfusion imaging (Winchester et al [ACC et al] 2023; Greenland et al [ACCF/AHA] 2010). This includes those who have an uninterpretable resting ECG or are unable to exercise or have an elevated  $\geq 400$  CAC (Agatston) score (Schindler et al [SNMMI et al] 2020: score 5; Schindler et al [SNMMI et al] 2020: score 6; Greenland et al [ACCF/AHA] 2010: level C evidence; PLE expert panel consensus opinion). It also includes patients with specific risk factors (e.g., diabetes, strong family history of CHD) (Knuuti et al [ESC] 2020: class IIb, level C evidence; Greenland et al [ACCF/AHA] 2010: level C evidence; Schindler et al [SNMMI et al] 2020: score 8).

### **Stress echocardiography**

Stress echocardiography is a test predominantly used in symptomatic patients to assist in the diagnosis of obstructive CAD (Greenland et al [ACCF/AHA] 2010). It is typically not recommended for asymptomatic adults with low or intermediate global risk of CAD (Winchester et al [ACC et al] 2023; Ghoshhajra et al [ACR] 2021; Greenland et al [ACCF/AHA] 2010; PLE expert panel consensus opinion), but may be considered for risk assessment in those with high risk (Greenland et al [ACCF/AHA] 2010: class III, level B evidence; Winchester et al [ACC et al] 2023).

### **Stress cardiac MRI (CMR)**

In low-risk asymptomatic adults, functional imaging for ischemia is not indicated for further diagnostic assessment (Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020: class III, level C recommendation). While MRI is typically not used for testing asymptomatic persons (Greenland et al [ACCF/AHA] 2010), the use of stress CMR may be appropriate in the detection of CAD among those with high global risk (Winchester et al [ACC et al] 2023; Kuuti et al [ESC] 2020: class IIb, level C recommendation).

### **Coronary CT angiography (CCTA)**

CCTA is typically not recommended for cardiovascular risk assessment in low- or intermediate-risk asymptomatic adults (Greenland et al [ACCF/AHA] 2010: level C evidence; Knuuti et al [ESC] 2020: class III, level C recommendation; Winchester et al [ACC et al] 2023). CCTA may be considered in high-risk asymptomatic adults (e.g., diabetes, strong family history of CAD) or when previous risk-assessment testing suggests a high risk of CAD (Knuuti et al [ESC] 2020: class IIb, level C recommendation; Ghoshhajra et al [ACR] 2021; Winchester et al [ACC et al] 2023).

### **Invasive coronary angiography**

Invasive coronary angiography is not recommended to assess risk in asymptomatic patients with no evidence of ischemia on noninvasive testing (Winchester et al [ACC et al] 2023).

### **Clinical and imaging notes:**

- A CAC score predicts atherosclerotic cardiovascular disease events in a graded fashion and is independent of other risk factors, such as age, sex, and ethnicity (Grundy et al [AHA] 2019).
- One purpose of CAC scoring is that it can reclassify risk identification of patients who will potentially benefit from statin therapy (Grundy et al [AHA] 2019; Ghoshhajra et al [ACR] 2021). CAC scoring is especially useful in older adults to improve specificity (Grundy et al [AHA] 2019).

### Evidence update (2016 - Present)

#### **Moderate Level of Evidence**

Bell et al (2022), in a systematic review and meta-analysis, evaluated the incremental value of CAC scans (CACs) above and beyond traditional cardiovascular risk assessment. Eligible studies were cohort studies in primary prevention populations that used a CVD risk calculator recommended by national guidelines (e.g., Framingham Risk Score) and assessed and reported incremental discrimination with CACS for estimating risk of a future cardiovascular event. A total of 6 eligible cohort studies were identified (total n = 1,043 CVD events in 17,961 participants). The C statistic (probability that a randomly selected patient experienced an event) for the CVD risk models without CACS ranged from 0.693 to 0.80. The pooled gain in C statistic from adding CACS was 0.036 (95%CI, 0.020-0.052). Among participants classified as being at low risk by risk score and reclassified as intermediate or high risk by CACS, 85.5% (65 of 76) to 96.4% (349 of 362) did not have a CVD event during follow-up. Among participants classified as being at high risk by risk score and reclassified as being at low risk by CACS, 91.4% (202 of 221) to 99.2% (502 of 506) did not have a CVD event during follow-up. The authors conclude that CACS appear to add some further discrimination to traditional CVD risk assessment equations, but the modest gain may be outweighed by incidental findings or radiation risks. Although CACS may have a role for refining risk assessment in selected patients, which patients would benefit remains unclear.

#### **Low Level of Evidence**

Dudum et al (2019), in a multi-center retrospective cohort study of 14,169 asymptomatic individuals, sought to assess consideration of CAC scoring in low-risk individuals (< 5%) with a family history of coronary heart disease (CHD). All CAC scans (93% using electron beam tomography with remainder utilizing MDCT) were physician referred and performed in patients without history of CHD. Individuals were followed for an average of 11.6 years. The event rate for all-cause mortality was 1.2 per 1,000 person-years, 0.3 per 1,000 person-years for CVD-specific mortality, and 0.2 per 1,000 person-years for CHD-specific mortality. In multivariable Cox proportional hazard models, those with CAC > 100 had a 2.2 (95% CI 1.5–3.3) higher risk of all-cause mortality, 4.3 (95% CI 1.9–9.5) times higher risk of CVD-specific mortality, and a 10.4 (95% CI 3.2–33.7) times higher risk of CHD-specific mortality compared to individuals with CAC=0. The authors conclude that in otherwise low risk patients with family history of CHD, CAC > 100 was associated with increased risk of all-cause/CHD mortality.

---

## PICO 2: Initial testing for symptomatic patient with no known coronary artery disease

### Low pretest probability:

- **Green** – Stress ECG
- **Yellow** – Stress echocardiography
- **Yellow** – Coronary CT angiography
- **Yellow** – CT coronary artery calcium
- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress cardiac MRI
- **Red** – Invasive coronary angiography

### Intermediate pretest probability:

- **Green** – Stress ECG
- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Coronary CT angiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – CT coronary artery calcium
- **Red** – Invasive coronary angiography

### High pretest probability:

- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Stress cardiac MRI
- **Green** – Coronary CT angiography
- **Green** – Invasive coronary angiography
- **Green** – Stress ECG
- **Yellow** – CT coronary artery calcium

### History of new-onset heart failure, exercise-induced or sustained ventricular tachycardia, ventricular fibrillation, or frequent PVCs with suspected underlying CAD:

- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Stress cardiac MRI
- **Green** – Invasive coronary angiography
- **Green** – Coronary CT angiography
- **Yellow** – Stress ECG
- **Red** – CT coronary artery calcium

Level of Evidence: coronary CT angiography: high; stress radionuclide myocardial perfusion imaging: high; stress cardiac MRI: moderate; CT coronary artery calcium: low; stress echocardiography: high

Notes concerning applicability and/or patient preferences: The approach to the diagnostic evaluation of patients with no known CAD should be guided by the ability to achieve high-quality imaging as well as local availability and expertise (Gulati et al [AHA et al] 2021). It is recommended to take account for locally available technology, the person and their preferences, and any contraindications (e.g., disabilities, frailty, limited ability to exercise, claustrophobia, metal implants, allergy to contrast) when deciding on the imaging method (NICE 2016). If more than one modality falls into the same appropriate use category, it is assumed that clinician judgment; test advantages and disadvantages; and available local expertise, facilities, and equipment will be considered to determine the optimal test for an individual patient (Winchester et al [ACC et al] 2023). The patient should be engaged in a process of shared decision-making before determining the final choice of the cardiac test modality (Gulati et al [AHA et al] 2021).

When considering testing that includes an exercise component, it should be assumed that the patient has no limitations that would preclude exercising to a symptomatic endpoint, achieving at least 80% of their age- and sex-predicted workload or  $\geq 85\%$  of their age-predicted maximal heart rate (Winchester et al [ACC et al] 2023). Similarly, it should be assumed that the ECG is interpretable. Baseline abnormalities that prevent interpretation of the ST-segment changes during stress includes those ECGs with resting abnormalities, such as ST-segment depression ( $\geq 0.10$  mV), left bundle branch block (LBBB), Wolff-Parkinson-White syndrome, digoxin use, or a ventricular paced rhythm that would make the exercise ECG difficult to interpret (Knuuti et al [ESC] 2020; PLE expert panel consensus opinion).

In the recommendations, 64-slice CT is generally required as a minimum threshold for coronary CT angiography, which may limit accessibility.

Guideline and PLE expert panel consensus opinion summary:

**Clinical risk assessment and stratification**

When symptoms are present and there is sufficient suspicion of heart disease to warrant cardiac evaluation, it is helpful to first estimate a patient's pretest probability of CAD (Shah et al [ACR] 2018; Knuuti et al [ESC] 2020). The performance of available tests for the diagnosis of CAD depends on the prevalence of disease in the tested population. When the risk is low, a negative test will effectively rule out disease, however testing will result in an increased number of false positives. When the risk is high, a negative test will not effectively rule out disease. Testing results in an increased number of false negative tests. Diagnostic testing is most useful when the likelihood of disease is intermediate (Knuuti et al [ESC] 2020).

A clinical risk assessment tool can help stratify patients into low, intermediate, or high pretest probability of CAD (Shah et al [ACR] 2018). Stratification of risk in these tools generally uses criteria such as patient age, sex, family history of CAD, type of chest pain, lipid levels, and previous cardiovascular events (Litmanovich et al [ACR] 2021).

The *Diamond-Forrester* model (Diamond & Forrester, 1979) was among the first to be used for classifying pretest probabilities (PTPs) and is commonly used to this day. However, some studies note that this model may overestimate the probability of CAD (e.g., Genders et al 2011; Reeh et al 2018), and recent analyses of contemporary data have demonstrated that the pretest probability of obstructive CAD based on age, sex, and the nature of the patient's symptoms is much lower than that published in previous guidelines (Gulati et al [AHA et al] 2021; Knuuti et al [ESC] 2020; Juarez-Orozco et al 2019; Foldyna et al 2018) (See table 1). Overestimation of PTP is an important contributory factor to a low diagnostic yield of non-invasive testing (Knuuti et al [ESC] 2020). Use of the more contemporary

guidelines results in a significant number of patients for whom diagnostic testing is not recommended. Studies have shown that outcomes in patients with the new PTP is good with an annual risk of cardiovascular death or MRI <1% (Knuuti et al [ESC] 2020).

**Table 1: Estimates of PTP of obstructive CAD using the Diamond Forrester model versus contemporary data.**

Age (years)	Sex	Typical Angina		Atypical Chest Pain		Non-anginal	
		Diamond-Forrester*	Contemporary Data**	Diamond-Forrester*	Contemporary Data**	Diamond-Forrester*	Contemporary Data**
30-39	Men	10-90%	<5%	10-90%	<5%	5-10%	<5%
30-39	Women	10-90%	<5%	<5%	<5%	<5%	<5%
40-49	Men	>90%	>15%	10-90%	5-15%	10-90%	<5%
40-49	Women	10-90%	5-15%	5-10%	5-15%	<5%	<5%
50-59	Men	>90%	>15%	10-90%	>15%	10-90%	5-15%
50-59	Women	10-90%	5-15%	10-90%	5-15%	5-10%	<5%
60-69	Men	>90%	>15%	10-90%	>15%	10-90%	>15%
60-69	Women	>90%	>15%	10-90%	5-15%	10-90%	5-15%
70+	Men	>90%	>15%	10-90%	>15%	10-90%	>15%
70+	Women	>90%	>15%	10-90%	>15%	10-90%	5-15%

(Diamond & Forrester 1979; Wolk et al [ACCF et al] 2014; Knuuti et al [ESC] 2020; Juarez-Orozco et al 2019; Foldyna et al 2018; Reeh et al 2018; Cheng et al 2011)

\***High:** > 90% pre-test probability. **Intermediate:** between 10% and 90% pre-test probability. **Low:** between 5% and 10% pre-test probability. **Very Low:** <5% pre-test probability.

\*\***>15%** denotes groups in which non-invasive testing is most beneficial. **5%-15%** denotes the groups in which testing for diagnosis may be considered after assessing the overall clinical likelihood based on modifiers. **<5%** denotes groups that have such a low probability of disease that diagnostic testing should be performed for only compelling reasons.

With these updated PTPs, patients with a PTP < 5% can often be assumed to have such a low probability of disease that diagnostic testing should only be performed for compelling reasons. When the PTP is 5-15%, patient preference, local resources / availability of tests, clinical judgment, and appropriate patient information remain important considerations when making a decision to proceed with non-invasive diagnostic testing (Knuuti et al [ESC] 2020). Recent validation studies have shown that the new ESC classification is well-calibrated, may improve disease prediction, and can change the downstream diagnostic pathway in a significant proportion of cases (e.g., Winther et al 2021; Lopes et al 2020; Bittencourt et al 2016; Carli & Gupta 2019; Baskaran et al 2019).

Models that incorporate information concerning risk factors for CVD, resting ECG changes, or coronary calcification scores can further improve risk assessment, compared with age, sex, and symptoms alone (Knuuti et al [ESC] 2020). Both the presence of clinical risk factors such as diabetes, dyslipidemia, family history of early CVD, or smoking history and abnormalities on resting ECG increase the probability of obstructive CAD (Knuuti et al [ESC] 2020). Together, these factors may be important in refining the likelihood obstructive CAD in patients with a PTP of 5-15% (Knuuti et al [ESC] 2020).

Basic first-line testing in symptomatic patients may include standard laboratory testing, a resting ECG, possible ambulatory ECG monitoring, resting echocardiography and chest x-ray (Knuuti et al [ESC] 2020).

Chest radiography may also be indicated to evaluate for other potential cardiac, pulmonary, and thoracic causes of symptoms (Knuuti et al [ESC] 2020; Gulati et al [AHA et al] 2021: class I, level C-EO evidence). A resting ECG is recommended in patients without an obvious, noncardiac cause of chest pain, as Q-wave, ST-segment, or T-wave changes can be used to improve estimations of the PTP (Fihn et al [ACCF et al] 2012: class I, level B evidence; NICE 2016; Knuuti et al [ESC] 2020; Gulati et al [AHA et al] 2021: class I, level B-NR evidence). A resting echocardiography can be useful to assess cardiac structure and function (Fihn et al [ACCF et al] 2012: class I, level B evidence; Knuuti et al [ESC] 2020). After clinical assessment and initial workup, many individuals diagnosed with non-anginal chest pain may not require further diagnostic imaging (NICE 2016; Winchester et al [ACC et al] 2023).

### **CT CAC**

If, after quantitative risk assessment and first-line testing, a risk-based treatment decision is still uncertain, assessment of CT CAC score, family history, high-sensitivity C-reactive protein (hs-CRP), and/or ankle-brachial index (ABI) may also be considered to inform treatment decision making (Goff et al [ACC/AHA] 2014: class IIb recommendation, level B evidence). Detection of significant coronary artery calcification on CT CAC can be used to improve estimations of the pretest probability (PTP) of obstructive CAD (Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020; Litmanovich et al [ACR] 2021; Gulati et al [AHA et al] 2021). In patients presenting with stable angina, a positive CT CAC score is more accurate than clinical risk stratification tools for determining which patients have CAD and is also predictive of which patients may have significant stenosis or those in need of additional diagnostic testing (Gulati et al [AHA et al] 2021; Shah et al [ACR] 2018). A CT CAC score of “zero” does not always exclude significant coronary plaque burden, however, and additional testing may still be necessary (Shah et al [ACR] 2018; Knuuti et al [ESC] 2020).

### **Stress ECG**

Stress ECG is a useful test in symptomatic patients with no known coronary disease and no prior testing when a noncardiac explanation (e.g., gastroesophageal reflux, COPD, pleurisy) is unlikely (Winchester et al [ACC et al] 2023). Stress ECG has inferior diagnostic performance compared with diagnostic imaging tests and has limited power to rule-in or rule-out obstructive CAD (Knuuti et al [ESC] 2020; Gulati et al [AHA et al] 2021). In patients with a low pretest probability of obstructive CAD, stress ECG testing has a reported negative predictive value (NPV) of 98%-99% and is reasonable as a first-line test for excluding myocardial ischemia and determining functional capacity (Fihn et al [ACCF et al] 2012: class IIa, level C evidence; Gulati et al [AHA et al] 2021: class IIa, level B-NR evidence). However, its positive predictive value (PPV) in low risk patients is limited, and therefore stress ECG alone should not be used in this population (NICE 2016; Knuuti et al [ESC] 2020). Stress ECG may also be considered as an alternative test to rule-in/rule-out CAD when non-invasive imaging is not available (Knuuti et al [ESC] 2020: class IIb, level B evidence). Stress ECG testing is generally recommended for patients with an intermediate or high pretest probability of CAD (Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class I, level A evidence; Gulati et al [AHA et al] 2021: class 2a, level B-R evidence), unless the patient is incapable of at least moderate physical functioning (Fihn et al [ACCF et al] 2012: class III, level C evidence).

### **Coronary CT angiography (CCTA)**

CCTA has been shown to be of value in CAD imaging because of its high NPV (Shah et al [ACR] 2018; Litmanovich et al [ACR] 2021). It is recommended as an initial test for diagnosing symptomatic patients when obstructive CAD cannot be excluded by clinical assessment alone (Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020: class I, level B recommendation). CCTA has superior diagnostic accuracy compared to other noninvasive examinations, provides coronary artery stenosis evaluation comparable to that of catheterization, and may allow for more appropriate selection of patients for downstream

testing (Knuuti et al [ESC] 2020; Shah et al [ACR] 2018; Litmanovich et al [ACR] 2021).

In general, CCTA is preferred in patients with a lower range of clinical likelihood of CAD, no previous diagnosis of CAD, and characteristics associated with a high likelihood of good image quality (Knuuti et al [ESC] 2020; Shah et al [ACR] 2018).

For patients with intermediate or high pretest probability of CAD, CCTA is also reasonable (Fihn et al [ACCF et al] 2012; class IIa/IIb, level B/level C evidence; Winchester et al [ACC et al] 2023; Litmanovich et al [ACR] 2021; Gulati et al [AHA et al] 2021: class I, level A evidence), because the “real” risk may be much lower than previously expected based on the newer PTP models proposed by the ESC (Knuuti et al [ESC] 2020; PLE expert panel consensus opinion). CCTA can also be offered if clinical assessment indicates non-anginal chest pain but resting ECG indicates ST-T changes or Q waves (NICE 2016). The use of CCTA may be appropriate for detection of CAD when any of the following conditions are present: newly diagnosed heart failure, ventricular tachycardia, ventricular fibrillation, or frequent premature ventricular contractions (PVCs) (Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020; White et al [ACR] 2018).

CCTA is not recommended when extensive coronary calcification, irregular heart rate, significant obesity, inability to cooperate with breath-hold commands, or any other conditions make obtaining good image quality unlikely (Knuuti et al [ESC] 2020: class III, level C evidence).

### **Stress radionuclide myocardial perfusion imaging (PET or SPECT)**

Non-invasive functional (stress) imaging is a core component of the diagnostic pathway and is recommended for many symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone (Knuuti et al [ESC] 2020: class I, level B recommendation; Winchester et al [ACC et al] 2023; Shah et al [ACR] 2018). Noninvasive functional testing for ischemia have better “rule-in” power and result in fewer downstream referrals for ICA compared to anatomic imaging (Knuuti et al 2020). Stress imaging is recommended for the detection of CAD in symptomatic patients with intermediate or high pre-test probability of CAD (Gulati et al [AHA et al] 2021: class I, level B-R evidence; Litmanovich et al [ACR] 2021; Fihn et al [ACCF et al] 2012: class I/class IIa, level B evidence; Winchester et al [ACC et al] 2023; Schindler et al [SNMMI et al] 2020: score 7, score 8, score 9). Among such patients, PET may be preferred to SPECT, if available, to improve diagnostic accuracy and decrease the rate of nondiagnostic test results (Gulati et al [AHA et al] 2021: class 2a, level B-R evidence). Stress imaging is also generally appropriate for detection of CAD for patients with any of the following conditions: newly diagnosed heart failure, ventricular tachycardia (VT), ventricular fibrillation, or frequent premature ventricular contractions (PVCs) (Winchester et al [ACC et al] 2023; White et al [ACR] 2018; Schindler et al [SNMMI] 2020; Fihn et al [ACCF et al] 2012: class IIb, level C evidence).

### **Stress cardiac MRI (CMR)**

Functional (stress) CMR provides high sensitivity and specificity for ischemia by the induction of wall motion abnormality (Shah et al [ACR] 2018). In general, the use of stress CMR is appropriate for patients with intermediate to high pre-test probability of CAD (Gulati et al [AHA et al] 2021: class I, level B-R evidence; Litmanovich et al [ACR] 2021; Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class IIa, level B evidence). The use of stress CMR is also generally appropriate for detection of suspected CAD in patients with any of the following conditions: newly diagnosed heart failure, ventricular tachycardia, ventricular fibrillation, or frequent premature ventricular contractions (PVCs) (Winchester et al [ACC et al] 2023; White et al [ACR] 2018). It can also be useful whenever echocardiographic examination is nondiagnostic (Shah et al [ACR] 2018). Stress CMR is typically not recommended for

patients with a low pre-test probability (Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class III (no benefit), level C evidence; PLE expert panel consensus opinion).

### **Stress echocardiography**

The prognostic value of stress echocardiography has been demonstrated in large observational series with low rates of CAD events for patients with normal test results, particularly those with good exercise tolerance (Gulati et al [AHA et al] 2021). It is primarily useful to evaluate for wall motion abnormalities, and can provide data regarding flow reserve, which can aid in patient risk stratification (Shah et al [ACR] 2018). For patients with a low pretest probability of obstructive IHD, standard stress echocardiography might be reasonable (Fihn et al [ACCF et al] 2012: class IIa/IIb, level C evidence; Shah et al [ACR] 2018). For patients with intermediate to high pretest probability, stress imaging with echocardiography is recommended (Gulati et al [AHA et al] 2021: class I, level B-R evidence; Litmanovich et al [ACR] 2021; Fihn et al [ACCF et al] 2012: class I/class IIa, level B evidence; Winchester et al [ACC et al] 2023; Shah et al [ACR] 2018). In any situation where a SPECT MPI study cannot be performed, stress echocardiogram may be substituted (Shah et al [ACR] 2018). The use of stress echocardiography is also generally appropriate for detection of CAD in patients with newly diagnosed heart failure, ventricular tachycardia, ventricular fibrillation, or frequent premature ventricular contractions (PVCs) (Winchester et al [ACC et al] 2023; White et al [ACR] 2018).

### **Invasive coronary angiography:**

Invasive coronary angiography is not recommended to assess low risk patients who have not undergone noninvasive risk testing (Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class III, level C evidence). It can be offered when the results of non-invasive anatomical and functional imaging are both inconclusive (NICE 2016; Knuuti et al [ESC] 2020: class IIa, level B evidence). In patients with a high clinical likelihood of CAD, severe symptoms refractory to medical therapy, or typical angina at a low level of exercise, proceeding directly to coronary angiography is a reasonable option for depicting the anatomy and severity of obstructive CAD and other coronary abnormalities (Winchester et al [ACC et al] 2023; Knuuti et al [ESC] 2020: class I, level B evidence; Maron et al 2020; Litmanovich et al [ACR] 2021). However, contemporary randomized trials support that candidates for elective coronary angiography may instead be safely triaged using CCTA or noninvasive stress testing (Gulati et al [AHA et al] 2021). The use of invasive coronary angiography is also generally appropriate for detection of CAD in patients with newly diagnosed heart failure, ventricular tachycardia, ventricular fibrillation, or frequent premature ventricular contractions (PVCs) (Winchester et al [ACC et al] 2023; White et al [ACR] 2018).

### Clinical notes:

- Symptomatic patients may present with any constellation of clinical findings consistent with CAD. Examples of likely anginal symptoms include chest pain or tightness, epigastric pain, shoulder pain, jaw pain, and chest pressure/discomfort, when occurring with exertion or emotional stress and relieved by rest, nitroglycerin, or both (Winchester et al [ACC et al] 2023).
- Less likely anginal symptoms include dyspnea or fatigue when not exertional and not relieved by rest/nitroglycerin, or occurring in a time frame not suggestive of angina (Winchester et al [ACC et al] 2023).
- Echocardiography is an important clinical tool for the exclusion of alternative causes of chest pain and can aid in diagnosing concurrent cardiac disease, such as valvular heart diseases, heart failure, and most cardiomyopathies; however, these diseases often coexist with obstructive CAD (Knuuti et al [ESC] 2020).

- In all cases, the imaging physician must select the appropriate combination of imaging parameters to acquire a diagnostic examination at a radiation dose that is as low as reasonably achievable (Shah et al [ACR] 2018).

#### Evidence update (2016-present):

##### **High Level of Evidence**

The DISCHARGE Trial Group (Kofoed et al 2023), in a multicenter randomized trial, assessed the comparative effectiveness of computed tomography (CCTA) and invasive coronary angiography (ICA) in patients with stable chest pain suspected to be caused by coronary artery disease (CAD). A total of 2,002 women and 1,559 men from 26 sites were referred for ICA with stable chest pain and pre-test probability of obstructive CAD of 10-60%. All patients were randomized 1:1 to a strategy of either CCTA or ICA as the initial diagnostic test (1,019 and 983 women, and 789 and 770 men, respectively), and an intention-to-treat analysis was performed. Outcomes were assessed by investigators blinded to randomization group. Follow-up at a median of 3.5 years was available for 99% of patients. The rate of major adverse cardiovascular events (MACE) did not differ between groups. In men, the expanded MACE composite (cardiovascular death, non-fatal MI, etc) endpoint occurred less frequently in the CCTA group than in the ICA group (22 (2.8%) v 41 (5.3%); hazard ratio 0.52, 95% CI: 0.31 to 0.87). In women, the risk of having a major procedure related complication was lower in the CCTA group than in the ICA group (3 (0.3%) v 21 (2.1%); hazard ratio 0.14, 0.04 to 0.46). The authors conclude that no evidence for a difference between use of CCTA and ICA as the initial diagnostic test was found in patients with intermediate pre-test probability of CAD. However, an initial CCTA scan was associated with fewer major procedure related complications in women and a lower frequency of the expanded MACE composite in men.

The DISCHARGE Trial Group (Maurovich-Horvat et al 2022), in a multicenter randomized trial, compared CTA with invasive coronary angiography (ICA) in guideline-directed management of stable chest pain. All patients were referred for ICA at one of 26 European centers and had intermediate pretest probability of obstructive CAD. The primary outcome was major adverse cardiovascular event over 3.5 years, with secondary outcome of procedure-related complications. A total of 3,561 patients were enrolled, with complete follow-up available for 3,523 (98.9%). Major adverse cardiovascular events occurred in 38 of 1,808 patients (2.1%) in the CTA group and 52 of 1,753 (3.0%) in the ICA group (hazard ratio, 0.70; 95% CI: 0.46-1.07; P = 0.10). Major procedure-related complications occurred in 9 patients (0.5%) in the CTA group and 33 (1.9%) in the ICA group (hazard ratio, 0.26; 95% CI: 0.13-0.55). Frequency of coronary revascularization procedures was lower in the CTA group than in the ICA group (256 patients [14.2%] vs. 315 patients [18.0%]; hazard ratio, 0.76; 95% CI: 0.65-0.90). Quality-of-life outcomes assessed at follow-up were also similar in the two groups, and medical therapy did not differ substantially between groups at follow-up. The authors conclude that a strategy of initial CTA resulted in no significant difference in the incidence of major adverse cardiovascular events as compared with ICA but was associated with a lower risk of major procedure-related complications and revascularization procedures.

Haase et al (2019), in a meta-analysis, examined whether CCTA should be performed in patients with any clinical probability of CAD. A total of 65 prospective diagnostic accuracy studies (n = 5,332) that examined CCTA with reference standard of coronary angiography, using  $\geq 50\%$  diameter reduction cutoff value for obstructive CAD, were included. All patients had a clinical indication for coronary angiography due to suspected CAD, and both tests were performed in all patients. Primary outcomes were positive (PPV) and negative (NPV) predictive values of CCTA as a function of clinical pretest probability of obstructive CAD. For a pretest probability range of 7-67%, the treat threshold of  $> 50\%$  and the no-treat threshold of  $< 15\%$  post-test probability were obtained using CCTA. At a pretest

probability of 7%, the PPV of CCTA was 50.9% (95% CI, 43.3%-57.7%) and the NPV of CCTA was 97.8% (96.4%-98.7%); corresponding values at a pretest probability of 67% were 82.7% (78.3%-86.2%) and 85.0% (80.2%-88.9%), respectively. The overall sensitivity of CCTA was 95.2% (92.6%-96.9%), specificity was 79.2% (74.9%-82.9%), and area under the curve was 0.897 (0.889-0.906). The authors conclude that the diagnosis of obstructive CAD using CCTA in patients with stable chest pain was most accurate when the clinical pretest probability was between 7%-67%.

The SCOT-HEART Investigators (2018), in an open-label, multi-center, parallel-group trial, randomly assigned patients with stable chest pain to standard care + CCTA (n = 2,073) or standard care alone (2,073) to determine the effect of CCTA on 5-year clinical outcomes. The primary end point was death from CHD or nonfatal myocardial infarction at 5 years. The 5-year rate of the primary end point was lower in the CCTA group than in the standard-care group (2.3% vs. 3.9%; hazard ratio, 0.59; 95% CI, 0.41 to 0.84; P = 0.004). Although rates of invasive coronary angiography and coronary revascularization were higher for CCTA group than standard-care group in the first few months of follow-up, overall rates were similar at 5 years. More preventive therapies were initiated in patients in the CCTA group (OR, 1.40; 95% CI, 1.19 to 1.65), as were more antianginal therapies (OR, 1.27; 95% CI, 1.05 to 1.54). There were no significant between-group differences in the rates of cardiovascular or noncardiovascular deaths or deaths from any cause. The authors conclude that the use of CCTA in addition to standard care in patients with stable chest pain resulted in a significantly lower rate of death from coronary heart disease or nonfatal myocardial infarction at 5 years than standard care alone, without resulting in a significantly higher rate of coronary angiography or coronary revascularization.

### **Moderate Level of Evidence**

Chow et al (2021), in a prospective cohort study, sought to confirm the incremental prognostic value of CCTA measured over a prolonged follow-up duration. Over a total of 99 months, 8,667 consecutive CCTA patients without history of myocardial infarction, revascularization, or congenital heart disease (mean age = 57.1) were prospectively enrolled and followed for a mean duration of 7 years. At follow-up, there were a total of 723 major adverse events (MAE), 278 major adverse cardiac events (MACE), 547 all-cause deaths, 110 cardiac deaths, and 104 non-fatal myocardial infarctions. Patients without coronary atherosclerosis at time of CCTA had very low annual event rate for both MAE and MACE (0.45%/year and 0.19%/year, respectively). Both MAE and MACE increased with increasing total plaque score and severity of CAD. Patients with high-risk CAD had annual MAE and MACE rates of 3.52%/year and 2.58%/year, respectively. The authors conclude that CCTA has independent and incremental prognostic value that is durable over time, and that the absence of coronary atherosclerosis portends an excellent prognosis.

Curzen et al (2021) tested whether an evaluation strategy based on fractional flow reserve using CCTA (FFR<sub>CT</sub>) would improve clinical outcomes compared with standard care. A total of 1,400 patients with stable chest pain in 11 centers were randomized to initial testing with CCTA with selective FFR<sub>CT</sub> (experimental group) or standard clinical care pathways (standard group). Most patients had an initial CCTA: 439 (63%) in the standard group vs. 674 (96%) in the experimental group, 254 of whom (38%) underwent FFR<sub>CT</sub>. Major adverse cardiac and cerebrovascular events did not differ significantly (10.2% in the experimental group vs. 10.6% in the standard group) and angina and quality of life improved to a similar degree over follow-up in both randomized groups. Invasive angiography was reduced significantly in the experimental group (19% vs. 25%, P = 0.01). The authors conclude that a strategy of CCTA with selective FFR<sub>CT</sub> in patients with stable angina did not differ significantly from standard clinical care pathways in clinical outcomes, but did reduce the use of invasive coronary angiography.

Yang et al (2019), in a meta-analysis, compared the diagnostic accuracy of stress myocardial perfusion imaging between CMR and nuclear medical imaging (SPECT or PET) for the diagnosis of hemodynamically significant CAD, with FFR as the reference standard. A total of 28 articles (n = 2,665) met the inclusion criteria and were included in the meta-analysis: 14 CMR, 13 SPECT, and 5 PET articles. The results demonstrated a pooled sensitivity of 0.88 (95% confidence interval [CI]: 0.80–0.93), 0.69 (95% CI: 0.56–0.79), and 0.83 (95% CI: 0.70–0.91), and a pooled specificity of 0.89 (95% CI: 0.85–0.93), 0.85 (95% CI, 0.80–0.89), and 0.89 (95% CI, 0.86–0.91) for CMR, SPECT, and PET, respectively. The area under the curve (AUC) of CMR, PET, and SPECT was 0.94 (95% CI, 0.92–0.96), 0.92 (95% CI, 0.89–0.94), and 0.87 (95% CI, 0.83–0.89), respectively. The authors conclude that CMR and PET both have high accuracy and SPECT has moderate accuracy to detect hemodynamically significant CAD.

Knuuti et al (2018), in a meta-analysis, aimed to determine the ranges of pre-test probability (PTP) of coronary artery disease (CAD) in which stress ECG, stress echocardiography, CCTA, SPECT, PET, and CMR can reclassify patients into a post-test probability that defines (> 85%) or excludes (< 15%) anatomically and functionally (defined by a fractional flow reserve [FFR] < 0.8) significant CAD. Studies with > 100 patients with stable CAD that utilized these techniques with either ICA or ICA + FFR as reference were included. A total of 28,664 patients from 132 studies that used ICA as reference, and 4,131 from 23 studies using FFR, were analyzed. Stress ECG was found to rule-in and rule-out anatomically significant CAD only when PTP was  $\geq 80\%$  (76–83%) and  $\leq 19\%$  (15–25%), respectively. CCTA was able to rule-in anatomic CAD at a PTP  $\geq 58\%$  (45–70%) and rule-out at a PTP  $\leq 80\%$  (65–94%). The corresponding PTP values for functionally significant CAD were  $\geq 75\%$  (67–83%) and  $\leq 57\%$  (40–72%) for CCTA, and  $\geq 71\%$  (59–81%) and  $\leq 27\%$  (24–31%) for ICA, demonstrating poorer performance of anatomic imaging against FFR. In contrast, functional imaging (PET, stress CMR, SPECT) was able to rule-in functionally significant CAD when PTP was  $\geq 46\%$ –59% and rule-out when PTP was  $\leq 34\%$ –57%. The authors conclude that selection of a diagnostic technique for any given patient to rule-in or rule-out CAD should be based on the optimal PTP range for each test and on the assumed reference standard.

Buckert et al (2018), in a prospective RCT, evaluated a CMR-based management approach for 200 patients with stable CAD. Patients with symptomatic CAD were randomized to diagnostic coronary angiography (group 1) or adenosine stress CMR (group 2). Primary endpoint was composite of cardiac death and nonfatal myocardial infarction. In group 1, 45 revascularizations (45.9%) were performed. In group 2, 27 patients (28.1%) were referred to revascularization because of ischemia on CMR. At 12-month follow-up, 7 primary events occurred: 3 in group 1 (event rate 3.1%) and 4 in group 2 (event rate 4.2%), with no statistically significant difference (p = 0.72). Over the next 2 years, 6 additional events were observed, giving a total of 4 events in group 1 and 9 events in group 2 (event rate 4.1% vs. 9.4%; p = 0.25). Group 2 showed significant quality-of-life improvement after 1 year in comparison to group 1. The authors conclude that a CMR-based strategy for stable CAD patients was safe, reduced revascularization procedure, and resulted in better quality of life at 12-mo follow-up, though noninferiority could not be proved.

### **Low Level of Evidence**

Grandhi et al (2022) used data from a prospective registry of 5,192 consecutive patients (mean age 53.5) with acute chest pain to evaluate the ability of coronary artery calcium (CAC) as an initial diagnostic tool to rule out obstructive CAD. All patients were at low to intermediate risk for acute coronary syndrome (ACS), and also underwent CCTA as the reference standard. Overall, 2,902 patients (56%) had CAC = 0, of which 135 (4.6%) had CAD (114 [3.9%] nonobstructive and 21 [0.7%] obstructive). Among those with CAC > 0, 23% had obstructive CAD. Sensitivity, specificity, PPV, and NPV of CAC testing to diagnose obstructive CAD were 96.2%, 62.4%, 22.4%, and 99.3%, respectively. The NPV for identifying those who

needed revascularization was 99.6%. Among patients with CAC = 0, 11 patients (0.4%) underwent revascularization, and the number needed to test with CCTA to detect 1 patient who required revascularization was 264. The authors conclude that integrating CAC testing very early in chest pain evaluation may be effective in appropriate triage of patients at low to intermediate risk of ACS.

Houssany-Pissot et al (2020) conducted a multicenter retrospective study of 4,952 patients to evaluate the rate of strictly normal invasive coronary angiogram (ICA) following a positive non-invasive test (functional testing (FT): n = 3,272 or CCTA: n = 1,676). Patients were categorized into five subgroups according to pre-test probability (PTP) of CAD. Results of ICA were defined as normal ICA, non-obstructive CAD (non-oCAD) and obstructive CAD (oCAD). Results found normal ICA in 819 patients, (16.5%), non-oCAD in 1,193 patients (24.1%), and oCAD in 2,940 patients (59.4%). Without considering PTP, CCTA compared to FT showed less frequently normal ICA (7% vs. 16.5%), and more frequent CAD (non-oCAD: 27.9% vs. 22.2%; oCAD: 65.1% vs. 56.4%) (all  $p < 0.0001$ ). When differences in PTP were considered, CCTA always showed lower rates of normal ICA than FT. In low and lower-intermediate risk patients, CCTA detected more frequent oCAD than FT ( $p < 0.001$ ). The authors conclude that CCTA is a better alternative than FT to limit unnecessary ICA, regardless of PTP value, without missing abnormal ICA.

---

### PICO 3: Follow-up/sequential\* testing for coronary artery disease:

Asymptomatic patient with low global CAD risk or last test performed > 90 days and < 2 years ago:

- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress echocardiography
- **Red** – Stress cardiac MRI
- **Red** – Coronary CT angiography
- **Red** – Stress ECG
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

Asymptomatic patient with intermediate-to-high global CAD risk and last test performed  $\geq$  2 years ago:

- **Yellow** – Stress ECG
- **Yellow** – Stress echocardiography
- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress cardiac MRI
- **Red** – Coronary CT angiography
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

Symptomatic patient with previous abnormal ECG or abnormal/equivocal stress ECG for CAD:

- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Stress cardiac MRI
- **Green** – Coronary CT angiography
- **Yellow** – Stress ECG
- **Yellow** – Invasive coronary angiography
- **Yellow** – CT coronary artery calcium

Symptomatic patient with previous coronary artery calcium (Agatston) score of < 100:

- **Yellow** – Stress ECG
- **Yellow** – Stress echocardiography
- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress cardiac MRI
- **Yellow** – Coronary CT angiography
- **Red** – Invasive coronary angiography

**Symptomatic patient with previous coronary artery calcium (Agatston) score of  $\geq 100$ :**

- **Green** – Stress ECG
- **Green** – Stress echocardiography
- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress cardiac MRI
- **Yellow** – Coronary CT angiography
- **Yellow** – Invasive coronary angiography

**Symptomatic patient with normal or mild ischemia on previous stress imaging (SPECT, PET, echo, or CMR):**

- **Green** - Coronary CT angiography
- **Yellow** - Invasive coronary angiography
- **Yellow** – CT coronary artery calcium
- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress echocardiography
- **Red** – Stress cardiac MRI
- **Red** – Stress ECG

**Symptomatic patient with moderate to severe ischemia on previous stress imaging (SPECT, PET, echo, or CMR):**

- **Green** - Coronary CT angiography
- **Green** - Invasive coronary angiography
- **Red** – CT coronary artery calcium
- **Red** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Red** – Stress echocardiography
- **Red** – Stress cardiac MRI
- **Red** – Stress ECG

**Symptomatic patient with previous CCTA that is normal or shows mild (<49%) stenosis:**

- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress echocardiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – Stress ECG
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

**Symptomatic patient with previous CCTA that is inconclusive or shows moderate (50-69%) stenosis:**

- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Stress cardiac MRI
- **Green** – Invasive coronary angiography
- **Yellow** – Stress ECG
- **Red** – CT coronary artery calcium

**Symptomatic patient with previous CCTA that shows severe stenosis:**

- **Green** – Invasive coronary angiography
- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress echocardiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – Stress ECG
- **Red** – CT coronary artery calcium

\*Refers to sequential testing being done as part of a continued patient evaluation or application of recent testing results in the reevaluation of a patient (Winchester et al [ACC et al] 2023).

Level of Evidence: coronary CT angiography: moderate; stress radionuclide myocardial perfusion imaging: moderate; stress cardiac MRI: moderate; stress echocardiography: moderate

Notes concerning applicability and/or patient preferences: It is recommended to take account for locally available technology and expertise, the person and their preferences, and any contraindications (e.g., disabilities, frailty, limited ability to exercise, claustrophobia, metal implants, allergy to contrast) when deciding on the imaging method (NICE 2016). If more than one modality falls into the same appropriate use category, it is assumed that physician judgment and available local expertise are used to determine the correct test for an individual patient (Winchester et al [ACC et al] 2023). The patient should be engaged in a process of shared decision-making before determining the final choice of the cardiac test modality (Gulati et al [AHA et al] 2021).

When considering testing that includes an exercise component, it should be assumed that the patient has no limitations that would preclude exercising to a symptomatic endpoint, achieving at least 80% of their age- and sex-predicted workload or  $\geq 85\%$  of their age-predicted maximal heart rate (Winchester et al [ACC et al] 2023). Similarly, it should be assumed that the ECG is interpretable. Baseline abnormalities that prevent interpretation of the ST-segment changes during stress includes those ECGs with resting abnormalities, such as ST-segment depression ( $\geq 0.10$  mV), left bundle branch block (LBBB), Wolff-Parkinson-White syndrome, digoxin use, or a ventricular paced rhythm that would make the exercise ECG difficult to interpret (Knuuti et al [ESC] 2020; PLE expert panel consensus opinion).

In the recommendations, 64-slice CT is generally required as a minimum threshold for coronary CT angiography, which may limit accessibility.

Guideline and PLE expert panel consensus opinion summary:

**Stress ECG**

In patients who have no new or worsening symptoms, no prior evidence of silent ischemia, and are not at high risk for a recurrent cardiac event, the usefulness of surveillance exercise ECG testing is not well established (Fihn et al [ACCF et al] 2012). However, standard exercise ECG testing might be considered for follow-up assessment in patients with prior evidence of silent ischemia or at high risk for a recurrent cardiac event who are able to exercise to an adequate workload and have an interpretable ECG (Fihn et al [ACCF et al]: class IIa, level C evidence). It can similarly be useful when prior CCTA or coronary angiography is abnormal or uncertain, or when prior CT CAC score is abnormal (Agatston score  $> 100$ ) (Winchester et al [ACC et al] 2023). Its use is not recommended in patients who are incapable of at least moderate physical functioning or have disabling comorbidity (Fihn et al [ACCF et al] 2012: class III, level C evidence), or have an abnormal prior stress study (Winchester et al [ACC et al] 2023).

### **Stress imaging: radionuclide myocardial perfusion imaging (PET or SPECT), cardiac MRI (CMR), or echocardiography**

After an initial stress ECG in symptomatic patients, data support an improved diagnostic accuracy and improved risk stratification with further stress imaging (Gulati et al [AHA et al] 2021; Winchester et al [ACC et al] 2023). Stress nuclear myocardial perfusion imaging, stress CMR, or stress echocardiography are generally recommended in symptomatic patients with any of the following (Winchester et al [ACC et al] 2023 Gulati et al [AHA et al] 2021: class 2a, level B-NR evidence; Knuuti et al [ESC] 2020: class IIb, level B recommendation; NICE 2016):

- Abnormal ECG
  - Inconclusive or abnormal exercise stress test
  - Previous CCTA with moderate stenosis 50%-69% (CAD-RADS 3)
  - Previous inconclusive CCTA
  - Previous CAC score > 100
- Invasive coronary angiography with intermediate severity and/or invasive physiological testing not performed

CMR may be considered in patients with suspected CAD when an echocardiogram (having used contrast) is inconclusive (Knuuti et al [ESC] 2020: class IIb, level C recommendation). In these patients, CMR can provide useful information on cardiac anatomy and systolic cardiac function (Knuuti et al [ESC] 2020: Class IIb, Level C recommendation). Non-invasive functional imaging for myocardial ischemia can be offered if CT coronary angiography has shown CAD of uncertain functional significance or is non-diagnostic (NICE 2016). The use of stress imaging may also be appropriate for risk assessment in patients with stable CAD who are being considered for revascularization of known coronary stenosis of unclear physiological significance (Fihn et al [ACCF et al] 2012: class I, level B evidence).

For confirmed CAD, non-invasive functional testing can be offered whenever there is uncertainty about whether the chest pain is being caused by myocardial ischemia (NICE 2016). Exercise with nuclear MPI, CMR, or echocardiography is reasonable in patients with known stable CAD who have new or worsening symptoms who have – a) at least moderate physical functioning and no disabling comorbidity, or b) previously required imaging with exercise stress, or c) known multivessel disease or high risk for multivessel disease (Fihn et al [ACCF et al] 2012: class I/IIa, level B evidence).

### **Coronary CT angiography**

CCTA is appropriate whenever there is discordance between prior ECG exercise testing and imaging results, or whenever prior stress imaging results are inconclusive (Gulati et al [AHA et al] 2021: class 2a, level B-NR evidence; Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class IIa, level C evidence). For intermediate-high risk patients with stable chest pain after a negative stress test but with high clinical suspicion of CAD, CCTA may be reasonable (Gulati et al [AHA et al] 2021: class 2a, level C-EO evidence). CCTA is also appropriate for symptomatic patients when prior CT CAC (e.g., Agatston score > 100), exercise ECG, or stress imaging results are abnormal and intervening revascularization is not pursued (Winchester et al [ACC et al] 2023). CCTA is not indicated for follow-up testing in symptomatic patients with prior invasive coronary angiography (Winchester et al [ACC et al] 2023). CCTA is also not recommended when conditions make good image quality unlikely, including extensive coronary calcification, irregular heart rate, significant obesity, inability to cooperate with breath-hold commands (Knuuti et al [ESC] 2020: class III, level C recommendation; Fihn et al [ACCF et al] 2012: class III (no benefit), level B evidence).

CCTA is not recommended as a routine follow-up test for patients with established CAD (Knuuti et al [ESC] 2020: class III, level C recommendation).

### **Invasive coronary angiography**

Invasive coronary angiography is not recommended to further assess risk in patients who have preserved LV function and lower-risk criteria on noninvasive testing (Fihn et al [ACCF et al] 2012: class III, level B evidence). Its use is also not typically recommended in patients with lower levels of previously detected coronary calcium (e.g., Agatston score < 100) (Winchester et al [ACC et al] 2023), but can be considered in patients with an abnormal prior exercise ECG or stress imaging study, when obstructive CAD is found on prior CCTA, or when Agatston score  $\geq$  100 (Winchester et al [ACC et al] 2023). For intermediate-high risk patients with stable chest pain after a negative stress test but with high clinical suspicion of CAD, invasive coronary angiography may be reasonable (Gulati et al [AHA et al] 2021: class 2a, level C-EO evidence). Invasive coronary angiography is recommended for patients whose clinical characteristics and results of noninvasive testing indicate a high likelihood of severe ischemic heart disease and the benefits are deemed to exceed risk (Fihn et al [ACCF et al] 2012: class I, level C evidence; Wolk et al [ACCF et al] 2014). It is also reasonable to further assess risk in those with depressed LV function and moderate risk criteria on noninvasive testing with demonstrable ischemia (Fihn et al [ACCF et al] 2012: class IIa, level C evidence), and in patients with inconclusive prognostic information after noninvasive testing (or when noninvasive testing is contraindicated or inadequate) (Fihn et al [ACCF et al] 2012: class IIa, level C evidence). In patients with a long-standing diagnosis of chronic coronary syndrome, its use is recommended for risk stratification in patients with severe CAD, particularly if the symptoms are refractory to medical treatment or if they have a high-risk clinical profile (Knuuti et al [ESC] 2020: class I, level C evidence). Its use is also reasonable for patients with who have unsatisfactory quality of life due to angina, have preserved LV function, and have intermediate risk criteria on noninvasive testing (Fihn et al [ACCF et al] 2012: class IIa, level C evidence).

### Clinical notes:

- Patients with stable CAD should receive periodic follow-up, at least annually, to include the following: assessment of symptoms and clinical function; surveillance for complications; monitoring of cardiac risk factors; and assessment of the adequacy of and adherence to recommended lifestyle changes and medical therapy (Fihn et al [ACCF et al] 2012).
- For revascularization decisions, information on both anatomy and ischemia is needed (Knuuti et al [ESC] 2020).

### Evidence update (2016-present):

#### **Low Level of Evidence**

Pezel et al (2021) assessed the long-term prognostic value of vasodilator stress perfusion CMR in asymptomatic patients with obstructive CAD. Consecutive patients referred for CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined as cardiovascular mortality or recurrent non-fatal myocardial infarction (MI). Known obstructive CAD was defined by history of PCI, CABG, or myocardial infarction. A total of 1,529 patients were enrolled, with 1,342 patients (87.8%; mean age 67.7 years) completing the follow-up (median 8.3 years). A total of 195 had MACE (14.5%). Patients without stress-induced myocardial ischemia had a low annualized rate of MACE (2.4%), whereas the annualized rate of MACE was higher for those with mild (7.3%), moderate (16.8%) or severe ischemia (42.2%);  $P < 0.001$ ). In multivariable stepwise Cox regression, myocardial ischemia and late gadolinium enhancement (LGE) were independent predictors of MACE (HR 2.80; 95% CI: 2.10-3.73,  $p <$

0.001 and HR 1.51; 95% CI: 1.01-2.27;  $p = 0.045$ ). The authors conclude that vasodilator stress CMR-induced myocardial ischemia and LGE are good long-term predictors for the incidence of MACE in asymptomatic patients with obstructive CAD.

---

## PICO 4: Known coronary artery disease with prior revascularization (PCI or CABG)

**Symptomatic** patient (with anginal symptoms and/or symptoms similar to prior ischemic episode):

- **Green** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Green** – Stress echocardiography
- **Green** – Stress cardiac MRI
- **Green** – Invasive coronary angiography
- **Yellow** – Coronary CT angiography
- **Yellow** – Stress ECG
- **Red** – CT coronary artery calcium

**Asymptomatic** patient with incomplete previous revascularization; additional revascularization feasible:

- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress echocardiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – Stress ECG
- **Red** – Coronary CT angiography
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

**Asymptomatic** patient with prior left main coronary stent ( $\geq$  2-year interval):

- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress echocardiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – Stress ECG
- **Yellow** – Coronary CT angiography
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

**Asymptomatic** patient with  $\geq$  5-year interval after CABG or  $\geq$  2-year interval after PCI\*:

- **Yellow** – Stress radionuclide myocardial perfusion imaging (PET or SPECT)
- **Yellow** – Stress echocardiography
- **Yellow** – Stress cardiac MRI
- **Yellow** – Stress ECG
- **Yellow** – Coronary CT angiography
- **Red** – Invasive coronary angiography
- **Red** – CT coronary artery calcium

\*Advanced imaging is generally not appropriate for asymptomatic patients if performed more frequently than at a) 5-year intervals after CABG or b) 2-year intervals after PCI (Fihn et al [ACCF et al] 2012, class III: no benefit, level of evidence: C; Winchester et al [ACC et al] 2023).

Level of Evidence: stress radionuclide myocardial perfusion imaging: high; coronary CT angiography: moderate; stress cardiac MRI: moderate; stress echocardiography: moderate

Notes concerning applicability and/or patient preferences: It is recommended to take account for locally available technology and expertise, the person and their preferences, and any contraindications (e.g., disabilities, frailty, limited ability to exercise, claustrophobia, metal implants, allergy to contrast) when deciding on the imaging method (NICE 2016). If more than one modality falls into the same appropriate use category, it is assumed that physician judgment and available local expertise are used to determine the correct test for an individual patient (Winchester et al [ACC et al] 2023). The patient should be engaged in a process of shared decision-making before determining the final choice of the cardiac test modality (Gulati et al [AHA et al] 2021).

When considering testing that includes an exercise component, it should be assumed that the patient has no limitations that would preclude exercising to a symptomatic endpoint, achieving at least 80% of their age- and sex-predicted workload or  $\geq 85\%$  of their age-predicted maximal heart rate (Winchester et al [ACC et al] 2023). Similarly, it should be assumed that the ECG is interpretable. Baseline abnormalities that prevent interpretation of the ST-segment changes during stress includes those ECGs with resting abnormalities, such as ST-segment depression ( $\geq 0.10$  mV), left bundle branch block (LBBB), Wolff-Parkinson-White syndrome, digoxin use, or a ventricular paced rhythm that would make the exercise ECG difficult to interpret (Knuuti et al [ESC] 2020; PLE expert panel consensus opinion).

In the recommendations, 64-slice CT is generally required as a minimum threshold for coronary CT angiography, which may limit accessibility.

#### Guideline and PLE expert panel consensus opinion summary:

##### **Stress ECG**

In symptomatic post-revascularization patients, exercise ECG may be appropriate (Winchester et al [ACC et al] 2023). It may also be appropriate for asymptomatic patients with incomplete revascularization, or > 5 years after CABG or > 2 years after PCI (Winchester et al [ACC et al] 2023).

##### **Coronary CT angiography**

CCTA can be useful for the imaging of symptomatic post-revascularization (PCI or CABG) patients (Winchester et al [ACC et al] 2023), with an extremely high rate of graft disease accuracy (PLE expert panel consensus opinion). For patients who have stable chest pain with previous coronary revascularization, CCTA is reasonable to evaluate bypass graft or stent patency (for stents  $\geq 3$  mm) (Gulati et al [AHA et al] 2021: class 2a, level B-NR evidence). In those who have had prior CABG surgery who are suspected to have myocardial ischemia, CCTA is reasonable to evaluate for myocardial ischemia or graft stenosis or occlusion (Gulati et al [AHA et al] 2021: class 2a, level C-LD evidence). CCTA may also be useful to assess patency of prior left main coronary stents, and can identify in-stent re-stenosis (Fihn et al [ACCF et al] 2012: class IIb, level B evidence Litmanonovich et al [ACR] 2021).

CCTA should not be performed for assessment of native coronary arteries with moderate or severe calcification or with coronary stents < 3 mm (Fihn et al [ACCF et al] 2012: class III (no benefit), level B evidence; PLE expert panel consensus opinion). It is also not generally recommended for routine follow-up assessment after CABG or PCI in patients with stable symptoms or patients who are asymptomatic if performed more frequently than 5 year intervals following CABG or 2 year intervals following PCA (Fihn et al [ACCF et al] 2012: class III (no benefit), level C evidence; Winchester et al [ACC et al] 2023; PLE

expert panel consensus opinion).

### **Stress imaging: radionuclide myocardial perfusion imaging (PET or SPECT), cardiac MRI (CMR), or echocardiography**

The use of stress imaging is generally appropriate for symptomatic post-revascularization (PCI or CABG) patients (Winchester et al [ACC et al] 2023), including whenever there is uncertainty about whether chest pain is caused by myocardial ischemia (NICE 2016). In patients who have had prior CABG surgery presenting with stable chest pain who are suspected to have myocardial ischemia, it is reasonable to perform stress imaging to evaluate for myocardial ischemia with graft stenosis or occlusion (Gulati et al [AHA et al] 2021: class 2a, level C-LD evidence). It may be appropriate to evaluate asymptomatic patients with the following scenarios (Winchester et al [ACC et al] 2023; Fihn et al [ACCF et al] 2012: class IIa, level C evidence; Schindler et al [SNMMI et al] 2020: score 6):

- Incomplete revascularization and additional revascularization is feasible,
- Prior left main coronary stent,
- > 5 years after CABG, or
- > 2 years after PCI

Stress imaging is not recommended in asymptomatic patients with history of CABG of < 5 years or PCI < 2 years (Schindler et al [SNMMI et al] 2020: score 2; Fihn et al [ACCF et al] 2012: class III (no benefit), level C evidence; Winchester et al [ACC et al] 2023).

### **Invasive coronary angiography**

In symptomatic post-revascularization patients (PCI or CABG), invasive coronary angiography is appropriate whenever there are anginal symptoms (Winchester et al [ACC et al] 2023). In patients who have had prior CABG surgery presenting with stable chest pain whose noninvasive stress test results show moderate-to-severe ischemia, or in those suspected to have myocardial ischemia with indeterminate/nondiagnostic stress test, invasive coronary angiography is recommended for guiding therapeutic decision-making (Gulati et al [AHA et al] 2021: class I, level C-LD evidence). Its use is not appropriate for asymptomatic patients with previous history of CABG or PCI (Winchester et al [ACC et al] 2023).

#### Clinical notes:

- After revascularization, patients should be monitored vigilantly, because they are at greater risk for complications (Knuuti et al [ESC] 2020).
- To assess a patient's risk > 1 year after revascularization, an annual evaluation by a cardiovascular practitioner is warranted, even if the patient is asymptomatic (Knuuti et al [ESC] 2020).

#### Evidence update (2016-present):

##### **Moderate Level of Evidence**

Park et al (2022), randomly assigned 1,706 patients (mean age 64.7) with high-risk anatomical or clinical characteristic who had undergone previous PCI to a follow-up strategy of routine functional testing (nuclear stress testing, exercise ECG, or stress echocardiography) at 1 year after PCI or to standard care alone. The primary outcome was composite of death from any cause, MI, or hospitalization for unstable angina at 2 years. At 2 years, a primary-outcome event had occurred in 46 of 849 patients (Kaplan-Meier estimate, 5.5%) in the functional-testing group and in 51 of 857 (Kaplan-Meier estimate, 6.0%) in the standard-care group (hazard ratio, 0.90; 95% CI, 0.61 to 1.35; P = 0.62). There were no between-group differences with respect to the components of the primary outcome. At 2 years, 12.3% of the patients in

the functional-testing group and 9.3% in the standard-care group had undergone invasive coronary angiography (difference, 2.99 percentage points; 95% CI, -0.01 to 5.99), and 8.1% and 5.8% of patients, respectively, had undergone repeat revascularization (difference, 2.23 percentage points; 95% CI, -0.22 to 4.68). The authors conclude that follow-up with routine functional testing, compared with standard care alone, did not improve clinical outcomes at 2 years.

### **Low Level of Evidence**

Pezel et al (2021) assessed the long-term prognostic value of vasodilator stress perfusion CMR in asymptomatic patients with obstructive CAD. Consecutive patients referred for CMR were followed for the occurrence of major adverse cardiovascular events (MACE), defined as cardiovascular mortality or recurrent non-fatal myocardial infarction (MI). Known obstructive CAD was defined by history of PCI, CABG, or myocardial infarction. A total of 1,529 patients were enrolled, with 1,342 patients (87.8%; mean age 67.7 years) completing the follow-up (median 8.3 years). A total of 195 had MACE (14.5%). Patients without stress-induced myocardial ischemia had a low annualized rate of MACE (2.4%), whereas the annualized rate of MACE was higher for those with mild (7.3%), moderate (16.8%) or severe ischemia (42.2%);  $P < 0.001$ ). In multivariable stepwise Cox regression, myocardial ischemia and late gadolinium enhancement (LGE) were independent predictors of MACE (HR 2.80; 95% CI: 2.10-3.73,  $p < 0.001$  and HR 1.51; 95% CI: 1.01-2.27;  $p = 0.045$ ). The authors conclude that vasodilator stress CMR-induced myocardial ischemia and LGE are good long-term predictors for the incidence of MACE in asymptomatic patients with obstructive CAD.

Pontone et al (2016), in a prospective study, compared an anatomic (CCTA) versus a functional (stress-CMR) strategy in 600 symptomatic patients with previous myocardial revascularization procedures. Patients were divided evenly into the groups ( $n = 300$ ) and followed-up for subsequent noninvasive tests, invasive coronary angiography, revascularization procedures, cumulative effective radiation dose, and major adverse cardiac events. The mean follow-up for CCTA and stress-CMR groups was similar ( $773.6 \pm 345$  versus  $752.8 \pm 291$  days;  $P=0.21$ ). Compared with stress-CMR, CCTA was associated with a higher rate of subsequent noninvasive tests (28% vs 17%;  $P=0.0009$ ), invasive coronary angiography (31% vs 20%;  $P=0.0009$ ), and revascularization procedures (24% vs 16%;  $P=0.007$ ). Stress-CMR strategy was associated with a significant reduction of radiation exposure (59%;  $P<0.001$ ). Patients undergoing stress-CMR also showed a lower rate of major adverse cardiac events (5% vs 10%;  $P<0.010$ ).


**Guideline exclusions:**

- Patients who have features consistent with emergent conditions or who are treated acutely
- Evaluation of perioperative risk in patients undergoing non-coronary cardiac surgery
- Transesophageal echocardiogram (TEE)
- Vasospastic angina
- Primary diagnosis of syncope without ischemic equivalent
- Pregnant patients
- Pediatric patients
- AI applications

**AUC Revision History:**

<b><u>Revision Date:</u></b>	<b><u>New AUC Clinical Scenario(s):</u></b>	<b><u>Approved By:</u></b>
05/11/2021	n/a	CDI Quality Institute's Multidisciplinary Committee
09/27/2022	n/a	RAYUS Quality Institute's Multidisciplinary Committee
9/12/2023	n/a	RAYUS Quality Institute's Multidisciplinary Committee

Information on our evidence development process, including our conflicts of interest policy is available on our website at <https://rayusradiology.com/ple>



## Appropriateness of Advanced Imaging in Patients with Coronary Artery Disease (suspected or diagnosed): Bibliography

09/12/2023

Baskaran L, Daad I, Gransar H, Hartaigh BO, Schulman-Marcus J, Lin FY, Pena JM, Hunter A, Newby DE, Adamson PD, Min JK. A comparison of the updated Diamond-Forrester, CAD consortium, and CONFIRM history-based risk scores for predicting obstructive coronary artery disease in patients with stable chest pain: The SCOT-HEART coronary CTA cohort. *JACC Cardiovasc Imaging*. 2019; 12(7 Pt 2):1392-1400.

Bell KJ, White S, Hassan O, Zhu L, Scott AM, Clark J, Glasziou P. Evaluation of the incremental value of a coronary artery calcium score beyond traditional cardiovascular risk assessment: A systematic review and meta-analysis. *JAMA Intern Med*. 2022; e221262.

Bittencourt MS, Hulten E, Polonsky TS, Hoffman U, Nasir K, Abbata S, Di Carli M, Blankstein R. European Society of Cardiology-recommended coronary artery disease consortium pretest probability scores more accurately predict obstructive coronary disease and cardiovascular events than the Diamond and Forrester Score: The partners registry. *Circulation*. 2016; 134(3):201-211.

Buckert D, Witzel S, Steinacker JM, Rottbauer W, Bernhardt P. Comparing cardiac magnetic resonance-guided versus angiography-guided treatment of patients with stable coronary artery disease: Results from a prospective randomized controlled trial. *JACC Cardiovasc Imaging*. 2018; 11(7):987-996.

Chow BJ, Yam Y, Small G, Wells GA, Crean AM, Ruddy TD, Hossain A. Prognostic durability of coronary computed tomography angiography. *Eur Heart J Cardiovasc Imaging*. 2021; 22(3):331-338.

CMS Local Coverage Determination (LCD): Non-invasive fractional flow reserve (FFR) for stable ischemic heart disease (L38278). 2020.

Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, Chinnaiyan K, Choi AD<, Ghossajra B, Jacobs J, Kowek L, Lesser J, Maroules C, Rubin GD, Rybicki FJ, Shaw LJ, Williams MC, Williamson E, White CS, Villines TC, Blankstein R. CAD-RADS™ 2.0 – 2022 Coronary Artery Disease – Reporting and Data System.: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR) and the North American Society of Cardiovascular Imaging (NASCI). J Am Coll Radiol. 2022; 19(11):1185-1212.

Curzen N, Nicholas Z, Stuart B, Wilding S, Hill K, Shambrook J, Eminton Z, Ball D, Barrett C, Johnson L, Nuttall J, Fox K, Connolly D, O’Kane P, Hobson A, Chauhan A, Uren N, Mccann G, Berry C, Carter J, Roobottom C, Mamas M, Rajani R, Ford I, Doulas P, Hlatky M. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: The FORECAST randomized trial. Eur Heart J. 2021; 42(37):3844-3852.

Di Carli MF, Gupta A. Estimating pre-test probability of coronary artery disease. JACC Cardiovasc Imaging. 2019; 12(7 Pt 2):1401-1404.

DISCHARGE Trial Group (Kofoed KF et al). Comparative effectiveness of initial computed tomography and invasive coronary angiography in women and men with stable chest pain and suspected coronary artery disease: Multicenter randomized trial. BMJ. 2022; 379:e071133.

DISCHARGE Trial Group (Maurovich-Horvat et al). CT or invasive coronary angiography in stable chest pain. N Engl J Med. 2022; 386(17):1591-1602.

Driessen RS, Danad I, Stuijzand WJ, Raijmakers PG, Schumacher SP, van Diemen PA, Leipsic JA, Knuuti J, Underwood SR, vande Ven PM, van Rossum AC, Taylor CA, Knaapen P. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemic diagnosis. J Am Coll Cardiol. 2019; 73(2):161-173.

Dudum R, Dzaye O, Mirbolouk M, Dardari ZA, Orimoloye OA, Budoff MJ, Berman DS, Rozanski A, Miedema MD, Nasir K, Rumberger JA, Shaw L, Whelton SP, Graham G, Blaha MJ. Coronary artery calcium scoring in low risk patients with family history of coronary heart disease: Validation of the SCCT guideline approach in the coronary artery calcium consortium. J Cardiovasc Comput Tomogr. 2019; 13(3):21-25.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR, Smith SC, Spertus JA, Williams SV, American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126(25):3097-3137.

Foldyna B, Udelson JE, Karady J, Banerji D, Lu MT, Mayrhofer T, Bittner DO, Meyersohn NM, Emami H, Genders TS, Fordyce CB, Ferencik M, Douglas PS, Hoffmann U. Pretest probability for patients with suspected obstructive coronary artery disease: Re-evaluating Diamond-Forrester for the contemporary era and clinical implications: Insights from the PROMISE trial. *Eur Heart J Cardiovasc Imaging*. 2019; 20(5):574-581.

Genders TS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, Nieman K, Galema TW, Meijboom WB, Mollet NR, de Feyter PJ, Cademartiri F, Maffei E, Dewey M, Zimmermann E, Laule M, Pugliese F, Barbagallo R, Sinitsyn V, Bogaert J, Goetschalckx K, Schoepf UJ, Rowe GW, Schuijf JD, Bax JJ, de Graaf FR, Knuuti J, Kajander S, van Mieghem CA, Meijs MF, Cramer MJ, Gopalan D, Feuchtner G, Friedrich G, Krestin GP, Myriam Hunink MG, CAD Consortium. A clinical prediction rule for the diagnosis of coronary artery disease: Validation, updating, and extension. *Eur Heart J*. 2011; 32(11):1316-1330.

Ghoshhajra BB, Hedgire SS, Hurwitz Koweek LM, Beache GM, Brown RK, Davis AM, Hsu JY, Johnson TV, Kicska GA, Kligerman SJ, Litmanovich D, Maroules CD, Meyersohn N, Rabbat MG, Villines TC, Wann S, Abbbara S. ACR Appropriateness Criteria® asymptomatic patient at risk for coronary artery disease: 2021 update. *J Am Coll Radiol*. 2021; 18(5S):S2-S12.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lakcand DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Tomaselli GF, American College of Cardiology / American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014; 129(25 Suppl 2):S49-S73.

Grandhi GR, Mszar R, Cainzos-Achirica M, Rajan T, Latif MA, Bittencourt MS, Shaw LJ, Batlle JC, Blankstein R, Blaha MJ, Cury RC, Nasir K. Coronary calcium to rule out obstructive coronary artery disease in patients with acute chest pain. *JACC Cardiovasc Imaging*. 2022; 15(2):271-280.

Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW, American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2010; 56(25):e50-e103.

Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor AJ, Weintraub WS, Harrington RA, Abrams J, Anderson JL, Bates ER, Grines CL, Hlatky MA, Lichtenberg RC, Lindner JR, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Vogel RA, Wesley DJ, American College of Cardiology Foundation Clinical Expert Consensus Task Force; Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computed Tomography. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force. *Circulation*. 2007; 115(3):402-426.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani S, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019; 139(25):e1046-e1081.

Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021; 144(22):e368-e454.

Haase R, Schlattmann P, Gueret P, Andreini D, Pontone G, Alkadhi H, Hausleiter J, Garcia MJ, Leschka S, Meijboom WB, Zimmermann E, Gerber B, Schoepf UJ, Shabestari AA, Norgaard BL, Meijs MF, Sato A, Ovrehus KA, Diederichsen AC, Jenkins SM, Knuuti J, Hamdan A, Halvorsen BA, Mendoza-Rodriguez V, Rochitte CE, Rixe J, Wan YL, Langer C, Bettencourt N, Martuscelli E, Ghostine S, Buechel RR, Nikolaou K, Mickley H, Yang L, Zhang Z, Chen MY, Halon DA, Rief M, Sun K, Hirt-Moch B, Niinuma H, Marcus RP, Muraglia S, Jakamy R, Chow BJ, Kaufmann PA, Tardif JC, Nomura C, Kofoed KF, Laissy JP, Arbab-Zadeh A, Kitagawa K, Laham R, Jinzaki M, Hoe J, Rybicki FJ, Scholte A, Paul N, Tan SY, Yoshioka K, Rohle R, Schuetz GM, Schueler S, Coenen MH, Wieske V, Achenbach S, Budoff MJ, Laule M, Newby DE, Dewey M, COME-CCT Consortium. Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: Meta-analysis of individual patient data. *BMJ*. 2019; 365:|1945.

Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne H. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. *J Nucl Cardiol*. 2016; 23(3):606-639.

Houssany-Pissot S, Rosencher J, Allouch P, Bensouda C, Pilliere R, Cacoub L, Caussin C, El-Hadad S, Makowski S, Beverelli F, Cacoub P. Screening coronary artery disease with computed tomography angiogram should limit normal invasive coronary angiogram, regardless of pretest probability. *Am Heart J*. 2020; 223:113-119.

Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, Wijns W, Knuuti J. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. *Eur Heart J Cardiovasc Imaging*. 2019; 20(11):1198-1207.

Knuuti J, Ballo H, Juarez-Orozco LE, Saraste A, Kohl P, Saskia Rutjes AW, Juni P, Windecker S, Bax JJ, Wijns W. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: A meta-analysis focused on post-test disease probability. *Eur Heart J*. 2018; 39(35):3322-3330.

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020; 41(3):407-477.

Litmanovich D, Hurwitz Koweek LM, Ghoshhajra BB, Agarwal PP, Bourque JM, Brown RK, Davis AM, Fuss C, Johri AM, Kligerman SJ, Malik SB, Maroules CD, Meyersohn NM, Vasu S, Willines TC, Abbata S. ACR Appropriateness Criteria® chronic chest pain-high probability of coronary artery disease: 2021 update. *J Am Coll Radiol*. 2022; 19(5S):S1-S18.

Lopes P, Albuquerque F, Freitas P, Rocha B, Cunha G, Mendes G, Abecasis J, Santos A, Saraiva C, Mendes M, Ferreira A. Pre-test probability of obstructive coronary artery disease in the new guidelines: Too much, too little or just enough? ESC Congress 2020 – The Digital Experience. 29 August – 1 September 2020.

National Institute for Health and Care Excellence. Recent-onset chest pain of suspected cardiac origin: Assessment and diagnosis. NICE guideline CG95. 2010 (updated November 2016). Available from: <https://www.nice.org.uk/guidance/cg95>.

Norgaard BL, Peipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, Jensen JM, Mauri L, De Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis A, Park SJ, Christiansen EH, Kaltoft A, Lassen JF, Botker HE, Achenbach S, NXT Trial Study Group. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: The NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). *J Am Coll Cardiol*. 2014; 63(12):1145-1155.

Park DW, Kang DY, Ahn JM, Yun SC, Yoon YH, Hur SH, Lee CH, Kim WJ, Kang SH, Park CS, Lee BK, Suh JW, Yoon JH, Choi JW, Kim KS, Choi SW, Lee SN, Park SJ; POST-PCI Investigators. Routine functional testing or standard care in high-risk patients after PCI. *N Engl J Med*. 2022; 387(10):905-915.

Pezel T, Hovasse T, Kinnel M, Untersee T, Champagne S, Toupin S, Garot P, Sanguinetti F, Garot J. Prognostic value of stress cardiovascular magnetic resonance in asymptomatic patients with known coronary artery disease. *J Cardiovasc Magn Reson*. 2021; 23(1):19.

Pontone G, Andreini D, Guaricci AI, Rota C, Guglielmo M, Mushtaq S, Baggiano A, Beltrama V, Fusini L, Solbiati A, Segurini C, Conte E, Gripari P, Annoni A, Formenti A, Petulla M, Lombardi F, Muscogiuri G, Bartorelli AL, Pepi M. The STRATEGY study (stress cardiac magnetic resonance versus computed tomography coronary angiography for the management of symptomatic revascularized patients): Resources and outcomes impact. *Circ Cardiovasc Imaging*. 2016; 9(10):e005171.

Reeh J, Thering CB, Heitmann M, Hojberg S, Sorum C, Bech J, Husum D, Dominguez H, Sehestedt T, Hermann T, Hansen KW, Simonsen L, Galatius S, Prescott E. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. *Eur Heart J*. 2019; 40(18):1426-1435.

Schindler TH, Bateman TM, Berman DS, Chareonthaitawee P, De Blanche LE, Dilsizian V, Dorbala S, Gropler RJ, Shaw L, Soman P, Winchester DE, Verberne H, Ahuja S, Beanlands RS, Di Carli MF, Murthy VL, Ruddy TD, Schwartz RG. Appropriate use criteria for PET myocardial perfusion imaging. *J Nucl Med*. 2020; 61(8):1221-1265.

Schuijf JD, Shaw LJ, Wijns W, Lamb HJ, Poldermans D, de Roos A, van der Wall EE, Bax JJ. Cardiac imaging in coronary artery disease: Differing modalities. *Heart*. 2005; 91(8):1110-1117.

SCOT-HEART Investigators; Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah AS, Timmis AD, van Beek EJ, Williams MC. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med*. 2018; 379(10):924-933.

Shah AB, Kirsch J, Bolen MA, Batile JC, Brown RK, Eberhardt RT, Hurwitz LM, Inacio JR, Jin JO, Krishnamurthy R, Leipsic JA, Rajiah P, Singh SP, White RD, Zimmerman SL, Abbara S. ACR Appropriateness Criteria® chronic chest pain-noncardiac etiology unlikely-low to intermediate probability of coronary artery disease. *J Am Coll Radiol*. 2018; 15(11S):S283-S290.

US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, Barry MJ, Cughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. *JAMA*. 2018a; 320(3):272-280.

US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, Barry MJ, Cughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for cardiovascular disease risk with electrocardiography: US Preventive Service Task Force recommendation statement. *JAMA*. 2018b; 319(22):2308-2314.

Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, Buechel RR, Cuocolo A, van Eck-Smit BL, Flotats A, Hacker M, Hindorf C, Kaufmann PA, Lindner O, Ljungberg M, Lonsdale M, Manrique A, Minarik D, Scholte AJ, Slart RH, Tragardh E, de Wit TC, Hesse B, European Association of Nuclear Medicine (EANM). EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. *Eur J Nucl Med Mol Imaging*. 2015; 42(12):1929-1940.

White J, Bolen MA, Batile JC, Brown RK, Eberhardt RT, Hurwitz LM, Inacio JR, Jin JO, Krishnamurthy R, Leipsic JA, Rajiah P, Shah AB, Singh SP, Villines TC, Zimmerman SL, Abbara S. ACR Appropriateness Criteria® suspected new-onset and known nonacute heart failure. *J Am Coll Radiol*. 2018; 15(11S):S418-S431.

Winchester DE, Maron DJ, Blankstein R, Chang IC, Kirtane AJ, Kwong RY, Pellikka PA, Prutkin JM, Russell R, Sandhu AT. ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multimodality appropriate use criteria for the detection and risk assessment of chronic coronary disease. *J Am Coll Cardiol*. 2023; 81(25):2445-2467.

Winther S, Schmidt SE, Rasmussen LD, Juarez Orozco LE, Steffensen FH, Botker HE, Knuuti J, Bottcher M. Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease. *Eur Heart J*. 2021; 42(14):1401-1411.

Yang K, Yu SQ, Lu MJ, Zhao SH. Comparison of diagnostic accuracy of stress myocardial perfusion imaging for detecting hemodynamically significant coronary artery disease between cardiac magnetic resonance and nuclear medical imaging: A meta-analysis. *Int J Cardiol*. 2019; 293:278-285.